- Home
- MYGN vs OFIX Comparison
MYGN vs OFIX Comparison
Compare MYGN & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- OFIX
- Stock Information
- Founded
- MYGN 1991
- OFIX 1987
- Country
- MYGN United States
- OFIX United States
- Employees
- MYGN N/A
- OFIX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OFIX Medical/Dental Instruments
- Sector
- MYGN Health Care
- OFIX Health Care
- Exchange
- MYGN Nasdaq
- OFIX Nasdaq
- Market Cap
- MYGN 744.7M
- OFIX 648.7M
- IPO Year
- MYGN 1995
- OFIX N/A
- Fundamental
- Price
- MYGN $7.29
- OFIX $13.43
- Analyst Decision
- MYGN Hold
- OFIX Strong Buy
- Analyst Count
- MYGN 16
- OFIX 4
- Target Price
- MYGN $20.17
- OFIX $23.33
- AVG Volume (30 Days)
- MYGN 1.2M
- OFIX 235.2K
- Earning Date
- MYGN 05-06-2025
- OFIX 05-06-2025
- Dividend Yield
- MYGN N/A
- OFIX N/A
- EPS Growth
- MYGN N/A
- OFIX N/A
- EPS
- MYGN N/A
- OFIX N/A
- Revenue
- MYGN $837,600,000.00
- OFIX $799,491,000.00
- Revenue This Year
- MYGN $2.99
- OFIX $4.87
- Revenue Next Year
- MYGN $8.36
- OFIX $6.40
- P/E Ratio
- MYGN N/A
- OFIX N/A
- Revenue Growth
- MYGN 11.21
- OFIX 7.08
- 52 Week Low
- MYGN $7.35
- OFIX $12.08
- 52 Week High
- MYGN $29.30
- OFIX $20.73
- Technical
- Relative Strength Index (RSI)
- MYGN 25.95
- OFIX 33.59
- Support Level
- MYGN $7.69
- OFIX $12.72
- Resistance Level
- MYGN $8.27
- OFIX $14.20
- Average True Range (ATR)
- MYGN 0.56
- OFIX 0.77
- MACD
- MYGN 0.02
- OFIX -0.05
- Stochastic Oscillator
- MYGN 1.02
- OFIX 21.78
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.